Blogs
Welcome to Unibest's Blogs section! Here, you will find valuable insights and in-depth reports covering various topics related to drugs and diseases. Our blogs aim to provide an enhanced understanding of the clinical significance and breakthroughs your clients can make. Stay updated with the latest trends, technological advancements, and industry analyses as we dive deep into the world of pharmaceuticals, giving you the knowledge and resources you need to stay ahead of the competition.

Fostemsavir tromethamine

These are related to the Fostemsavir tromethamine news, in which you can learn about the updated information in Fostemsavir tromethamine, to help you better understand and expand Fostemsavir tromethamine market. Because the market for Fostemsavir tromethamine is evolving and changing, so we recommend that you collect our website, and we will show you the latest news on a regular basis.
  • Drug Patent & Exclusivity Expiration Report - Week of Feb 24 2025

    Drug Patent & Exclusivity Expiration Report - Week of Feb 24 2025

    2025-02-24

    This week, there are 12 drugs in the patent and exclusivity list. They are: - VIIV HEALTHCARE CO's RUKOBIA, containing active ingredient FOSTEMSAVIR TROMETHAMINE - BOEHRINGER INGELHEIM PHARMACEUTICALS INC's STIOLTO RESPIMAT, containing active ingredient OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE - BOEHRINGER INGELHEIM PHARMACEUTICALS INC's SPIRIVA RESPIMAT, containing active ingredient TIOTROPIUM BROMIDE - VIFOR PHARMA INC's VELTASSA, containing active ingredient PATIROMER SORBITEX CALCIUM - JANSSEN PHARMACEUTICALS INC's XARELTO, containing active ingredient RIVAROXABAN - TEVA PHARMACEUTICAL INDUSTRIES LTD's AIRDUO RESPICLICK, containing active ingredient FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - PF PRISM CV's XALKORI, containing active ingredient CRIZOTINIB - BOEHRINGER INGELHEIM PHARMACEUTICALS INC's JARDIANCE, containing active ingredient EMPAGLIFLOZIN Read More